Evidence map›Paper›PMID 38104307›Full record

ReviewCellular and molecular neurobiology2023

Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review.

Sushruta Ghosh, Gurjit Kaur Bhatti, Pushpender Kumar Sharma, Ramesh Kandimalla, Sarabjit Singh Mastana, Jasvinder Singh Bhatti

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Sushruta GhoshLaboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine, School of Health Sciences Central, University of Punjab, Bathinda, India.ORCID http://orcid.org/0009-0003-0382-5876
Gurjit Kaur BhattiDepartment of Medical Lab Technology, University Institute of Applied Health Sciences, Chandigarh University, Mohali, India.ORCID http://orcid.org/0000-0003-0575-7427
Pushpender Kumar SharmaAmity Institute of Biotechnology, Amity University, Rajasthan, India.ORCID http://orcid.org/0000-0003-0359-744X
Ramesh KandimallaDepartment of Biochemistry, Kakatiya Medical College, Warangal, Telangana, India.ORCID http://orcid.org/0000-0002-3313-4393
Sarabjit Singh MastanaSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.ORCID http://orcid.org/0000-0002-9553-4886
Jasvinder Singh BhattiLaboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine, School of Health Sciences Central, University of Punjab, Bathinda, India. jasvinder.bhatti@cup.edu.in.ORCID http://orcid.org/0000-0001-5480-2584
Central University of Punjab · INAmity University · AEChandigarh University · INKakatiya University · INLoughborough University · GB

Funding

SERB India EEQ/2020/000188
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic and degrading autoimmune disorder mainly targeting the central nervous system, leading to progressive neurodegeneration, demyelination, and axonal damage. Current treatment options for MS are limited in efficacy, generally linked to adverse side effects, and do not offer a cure. Stem cell therapies have emerged as a promising therapeutic strategy for MS, potentially promoting remyelination, exerting immunomodulatory effects and protecting against neurodegeneration. Therefore, this review article focussed on the potential of nano-engineering in stem cells as a therapeutic approach for MS, focusing on the synergistic effects of combining stem cell biology with nanotechnology to stimulate the proliferation of oligodendrocytes (OLs) from neural stem cells and OL precursor cells, by manipulating neural signalling pathways-PDGF, BMP, Wnt, Notch and their essential genes such as Sox, bHLH, Nkx. Here we discuss the pathophysiology of MS, the use of various types of stem cells in MS treatment and their mechanisms of action. In the context of nanotechnology, we present an overview of its applications in the medical and research field and discuss different methods and materials used to nano-engineer stem cells, including surface modification, biomaterials and scaffolds, and nanoparticle-based delivery systems. We further elaborate on nano-engineered stem cell techniques, such as nano script, nano-exosome hybrid, nano-topography and their potentials in MS. The article also highlights enhanced homing, engraftment, and survival of nano-engineered stem cells, targeted and controlled release of therapeutic agents, and immunomodulatory and tissue repair effects with their challenges and limitations. This visual illustration depicts the process of utilizing nano-engineering in stem cells and exosomes for the purpose of delivering more accurate and improved treatments for Multiple Sclerosis (MS). This approach targets specifically the creation of oligodendrocytes, the breakdown of which is the primary pathological factor in MS.

Indexed as

Multiple SclerosisNeural Stem CellsAxonsCentral Nervous SystemHumansMyelin SheathOligodendrogliaBiomarkersExosomesMultiple sclerosisNano-engineeringNanoscriptsStem cells

Identifiers

PMID38104307
PMCPMC11397842
OpenAlexW4389856611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.